Brief: Department Of Defense Awards Grant To Advance Tiziana’s Intranasal Anti-CD3 Therapy for Treating Spinal Cord Injury
15/09/2025 13:26
Sept 15 (Reuters) - Tiziana Life Sciences Ltd TLSA.O: DEPARTMENT OF DEFENSE AWARDS GRANT TO ADVANCE TIZIANA LIFE SCIENCES INTRANASAL ANTI-CD3 THERAPY FOR SPINAL CORD INJURY TIZIANA LIFE SCIENCES LTD: DOD AWARD WILL SUPPORT A THREE-YEAR STUDY OF INTRANASAL ANTI-CD3 IN ACUTE PHASE OF SCI Source text: ID:nGNX6sj2bB Further company coverage: TLSA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tiziana Life Sciences
See all newsTiziana's experimental MS treatment meets main goals in mid-stage study
Brief: Tiziana Life Sciences - Submits Request To FDA For Orphan Drug Designation For Intranasal Foralumab For Msa
Brief: Tiziana Announces Last Patient Completes Last Visit In Phase 2A Inform-MS Trial Of Intranasal Foralumab
Brief: Tiziana Announces Last Patient Successfully Dosed In Its Phase 2 Inform-MS Trial
Brief: Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis